Intranasal vaccination affords localization and persistence of antigen-specific CD8+ T lymphocytes in the female reproductive tract

Shailbala Singh, Kimberly S. Schluns, Guojun Yang, Scott M. Anthony, Michael A Barry, K. Jagannadha Sastry

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Immunization strategies generating large numbers of antigen-specific T cells in the female reproductive tract (FRT) can provide barrier protection against sexually-transmitted pathogens,such as the human immunodeficiency virus (HIV) and human papillomaviruses (HPV). The kinetics and mechanisms of regulation of vaccine-induced adaptive T cell-mediated immune responses in FRT are less well defined. We present here evidence for intranasal delivery of the model antigen ovalbumin (OVA) along with alpha-galactosylceramide adjuvant as a protein vaccine to induce significantly higher levels of antigen-specific effector and memory CD8+ T cells in the FRT, relative to other systemic and mucosal tissues. Antibody blocking of the CXCR3 receptor significantly reduced antigen-specific CD8+ T cells subsequent to intranasal delivery of the protein vaccine suggesting an important role for the CXCR3 chemokine-receptor signaling for T cell trafficking. Further, intranasal vaccination with an adenoviral vector expressing OVA or HIV-1 envelope was as effective as intramuscular vaccination for generating OVA-or ENV-specific immunity in the FRT. These results support the application of the needle-free intranasal route as a practical approach to delivering protein as well as DNA/virus vector-based vaccines for efficient induction of effector and memory T cell immunity in the FRT.

Original languageEnglish (US)
Article number7
JournalVaccines
Volume4
Issue number1
DOIs
StatePublished - Mar 17 2016

Fingerprint

CD8 Antigens
Vaccination
T-Lymphocytes
Ovalbumin
CXCR3 Receptors
Vaccines
Antigens
Immunity
Proteins
Blocking Antibodies
DNA Viruses
Chemokine Receptors
Needles
HIV-1
Immunization
Mucous Membrane
HIV

Keywords

  • CD8 T cells
  • Female reproductive tract
  • Intranasal immunization

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Intranasal vaccination affords localization and persistence of antigen-specific CD8+ T lymphocytes in the female reproductive tract. / Singh, Shailbala; Schluns, Kimberly S.; Yang, Guojun; Anthony, Scott M.; Barry, Michael A; Jagannadha Sastry, K.

In: Vaccines, Vol. 4, No. 1, 7, 17.03.2016.

Research output: Contribution to journalArticle

Singh, Shailbala ; Schluns, Kimberly S. ; Yang, Guojun ; Anthony, Scott M. ; Barry, Michael A ; Jagannadha Sastry, K. / Intranasal vaccination affords localization and persistence of antigen-specific CD8+ T lymphocytes in the female reproductive tract. In: Vaccines. 2016 ; Vol. 4, No. 1.
@article{3095e127c3324b708eb3f8720432a823,
title = "Intranasal vaccination affords localization and persistence of antigen-specific CD8+ T lymphocytes in the female reproductive tract",
abstract = "Immunization strategies generating large numbers of antigen-specific T cells in the female reproductive tract (FRT) can provide barrier protection against sexually-transmitted pathogens,such as the human immunodeficiency virus (HIV) and human papillomaviruses (HPV). The kinetics and mechanisms of regulation of vaccine-induced adaptive T cell-mediated immune responses in FRT are less well defined. We present here evidence for intranasal delivery of the model antigen ovalbumin (OVA) along with alpha-galactosylceramide adjuvant as a protein vaccine to induce significantly higher levels of antigen-specific effector and memory CD8+ T cells in the FRT, relative to other systemic and mucosal tissues. Antibody blocking of the CXCR3 receptor significantly reduced antigen-specific CD8+ T cells subsequent to intranasal delivery of the protein vaccine suggesting an important role for the CXCR3 chemokine-receptor signaling for T cell trafficking. Further, intranasal vaccination with an adenoviral vector expressing OVA or HIV-1 envelope was as effective as intramuscular vaccination for generating OVA-or ENV-specific immunity in the FRT. These results support the application of the needle-free intranasal route as a practical approach to delivering protein as well as DNA/virus vector-based vaccines for efficient induction of effector and memory T cell immunity in the FRT.",
keywords = "CD8 T cells, Female reproductive tract, Intranasal immunization",
author = "Shailbala Singh and Schluns, {Kimberly S.} and Guojun Yang and Anthony, {Scott M.} and Barry, {Michael A} and {Jagannadha Sastry}, K.",
year = "2016",
month = "3",
day = "17",
doi = "10.3390/vaccines4010007",
language = "English (US)",
volume = "4",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - Intranasal vaccination affords localization and persistence of antigen-specific CD8+ T lymphocytes in the female reproductive tract

AU - Singh, Shailbala

AU - Schluns, Kimberly S.

AU - Yang, Guojun

AU - Anthony, Scott M.

AU - Barry, Michael A

AU - Jagannadha Sastry, K.

PY - 2016/3/17

Y1 - 2016/3/17

N2 - Immunization strategies generating large numbers of antigen-specific T cells in the female reproductive tract (FRT) can provide barrier protection against sexually-transmitted pathogens,such as the human immunodeficiency virus (HIV) and human papillomaviruses (HPV). The kinetics and mechanisms of regulation of vaccine-induced adaptive T cell-mediated immune responses in FRT are less well defined. We present here evidence for intranasal delivery of the model antigen ovalbumin (OVA) along with alpha-galactosylceramide adjuvant as a protein vaccine to induce significantly higher levels of antigen-specific effector and memory CD8+ T cells in the FRT, relative to other systemic and mucosal tissues. Antibody blocking of the CXCR3 receptor significantly reduced antigen-specific CD8+ T cells subsequent to intranasal delivery of the protein vaccine suggesting an important role for the CXCR3 chemokine-receptor signaling for T cell trafficking. Further, intranasal vaccination with an adenoviral vector expressing OVA or HIV-1 envelope was as effective as intramuscular vaccination for generating OVA-or ENV-specific immunity in the FRT. These results support the application of the needle-free intranasal route as a practical approach to delivering protein as well as DNA/virus vector-based vaccines for efficient induction of effector and memory T cell immunity in the FRT.

AB - Immunization strategies generating large numbers of antigen-specific T cells in the female reproductive tract (FRT) can provide barrier protection against sexually-transmitted pathogens,such as the human immunodeficiency virus (HIV) and human papillomaviruses (HPV). The kinetics and mechanisms of regulation of vaccine-induced adaptive T cell-mediated immune responses in FRT are less well defined. We present here evidence for intranasal delivery of the model antigen ovalbumin (OVA) along with alpha-galactosylceramide adjuvant as a protein vaccine to induce significantly higher levels of antigen-specific effector and memory CD8+ T cells in the FRT, relative to other systemic and mucosal tissues. Antibody blocking of the CXCR3 receptor significantly reduced antigen-specific CD8+ T cells subsequent to intranasal delivery of the protein vaccine suggesting an important role for the CXCR3 chemokine-receptor signaling for T cell trafficking. Further, intranasal vaccination with an adenoviral vector expressing OVA or HIV-1 envelope was as effective as intramuscular vaccination for generating OVA-or ENV-specific immunity in the FRT. These results support the application of the needle-free intranasal route as a practical approach to delivering protein as well as DNA/virus vector-based vaccines for efficient induction of effector and memory T cell immunity in the FRT.

KW - CD8 T cells

KW - Female reproductive tract

KW - Intranasal immunization

UR - http://www.scopus.com/inward/record.url?scp=85016895700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016895700&partnerID=8YFLogxK

U2 - 10.3390/vaccines4010007

DO - 10.3390/vaccines4010007

M3 - Article

AN - SCOPUS:85016895700

VL - 4

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 1

M1 - 7

ER -